Genentech/Curis Hedgehog Inhibitor Gets Unclear Results In Ovarian Cancer Maintenance Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech/Roche will continue to follow data on GDC-0449 in the indication in light of signals that "warrant further investigation" and make a decision in coming months.
You may also be interested in...
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
Curis/Genentech Report Positive Phase II Results For Vismodegib
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.